{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:19:11Z","timestamp":1787530751544,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200549"],"award-info":[{"award-number":["RP200549"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75554-z","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:04:59Z","timestamp":1784646299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Domvanalimab plus zimberelimab in unresectable and immunotherapy refractory biliary tract cancers: a phase 2 trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9139-302X","authenticated-orcid":false,"given":"David","family":"Hsiehchen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Lohrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Kainthla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Mohammad Ali","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Manwaring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-9698","authenticated-orcid":false,"given":"Hao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"75554_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17, 557\u2013588 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"75554_CR2","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/cncr.33476","volume":"127","author":"G Ouyang","year":"2021","unstructured":"Ouyang, G. et al. The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study 2017. Cancer 127, 2238\u20132250 (2021).","journal-title":"Cancer"},{"key":"75554_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.21037\/cco.2016.10.03","volume":"5","author":"M Fairweather","year":"2016","unstructured":"Fairweather, M., Balachandran, V. P. & D\u2019Angelica, M. I. Surgical management of biliary tract cancers. Chin. Clin. Oncol. 5, 63 (2016).","journal-title":"Chin. Clin. Oncol."},{"key":"75554_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel, A. et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 127\u2013140 (2023).","journal-title":"Ann. Oncol."},{"key":"75554_CR5","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865 (2023).","journal-title":"Lancet"},{"key":"75554_CR6","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh, D. Y. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1, EVIDoa2200015 (2022).","journal-title":"NEJM Evid."},{"key":"75554_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-med-080222-100847","volume":"76","author":"EE Dumbrava","year":"2025","unstructured":"Dumbrava, E. E., Ben Haj Frej, K., Sharon, E. & Tawbi, H. Application and expectations for immune checkpoint blockade of LAG3 and TIGIT. Annu. Rev. Med. 76, 189\u2013205 (2025).","journal-title":"Annu. Rev. Med."},{"key":"75554_CR8","doi-asserted-by":"publisher","unstructured":"Hosseinkhani, N. et al. A systematic review and meta-analysis on the significance of TIGIT in solid cancers: dual TIGIT\/PD-1 blockade to overcome immune-resistance in solid cancers. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms221910389 (2021).","DOI":"10.3390\/ijms221910389"},{"key":"75554_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07984-4","volume":"16","author":"H Cui","year":"2025","unstructured":"Cui, H., Hamad, M. & Elkord, E. TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies. Cell Death Dis. 16, 664 (2025).","journal-title":"Cell Death Dis."},{"key":"75554_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta, K. L. et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses. Immunity 55, 512\u2013526 e519 (2022).","journal-title":"Immunity"},{"key":"75554_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1053\/j.gastro.2020.03.074","volume":"159","author":"DK Chiu","year":"2020","unstructured":"Chiu, D. K. et al. Hepatocellular carcinoma cells up-regulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice. Gastroenterology 159, 609\u2013623 (2020).","journal-title":"Gastroenterology"},{"key":"75554_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/CJI.0000000000000330","volume":"43","author":"C Zhang","year":"2020","unstructured":"Zhang, C. et al. TIGIT can exert immunosuppressive effects on CD8+ T cells by the CD155\/TIGIT signaling pathway for hepatocellular carcinoma in vitro. J. Immunother. 43, 236\u2013243 (2020).","journal-title":"J. Immunother."},{"key":"75554_CR13","doi-asserted-by":"publisher","first-page":"1942673","DOI":"10.1080\/2162402X.2021.1942673","volume":"10","author":"L Yu","year":"2021","unstructured":"Yu, L. et al. TIGIT(+) TIM-3(+) NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus\u2011related hepatocellular carcinoma. Oncoimmunology 10, 1942673 (2021).","journal-title":"Oncoimmunology"},{"key":"75554_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00262-025-04128-7","volume":"74","author":"EC Sundstrom","year":"2025","unstructured":"Sundstrom, E. C., Huang, X. & Wiemer, A. J. Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms. Cancer Immunol. Immunother. 74, 272 (2025).","journal-title":"Cancer Immunol. Immunother."},{"key":"75554_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07388-4","volume":"16","author":"T Tang","year":"2025","unstructured":"Tang, T. et al. TIGIT expression in extrahepatic cholangiocarcinoma and its impact on CD8 + T cell exhaustion: implications for immunotherapy. Cell Death Dis. 16, 90 (2025).","journal-title":"Cell Death Dis."},{"key":"75554_CR16","doi-asserted-by":"publisher","unstructured":"Heij, L. et al. TIGIT drives the immunosuppressive environment by downregulation of metalloproteinases MMP2 and MMP14 in perihilar cholangiocarcinoma. Preprint at BioRxiv https:\/\/doi.org\/10.1101\/2023.08.14.553195 (2023).","DOI":"10.1101\/2023.08.14.553195"},{"key":"75554_CR17","doi-asserted-by":"publisher","first-page":"736955","DOI":"10.3389\/fonc.2021.736955","volume":"11","author":"B Lou","year":"2021","unstructured":"Lou, B. et al. Preclinical characterization of GLS-010 (Zimberelimab), a novel fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Front. Oncol. 11, 736955 (2021).","journal-title":"Front. Oncol."},{"key":"75554_CR18","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1158\/0008-5472.CAN-23-2455","volume":"84","author":"D Piovesan","year":"2024","unstructured":"Piovesan, D. et al. Fc-silent anti-TIGIT antibodies potentiate antitumor immunity without depleting regulatory T cells. Cancer Res. 84, 1978\u20131995 (2024).","journal-title":"Cancer Res."},{"key":"75554_CR19","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1158\/1078-0432.CCR-19-3467","volume":"26","author":"AR Parikh","year":"2020","unstructured":"Parikh, A. R. et al. Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers. Clin. Cancer Res. 26, 1877\u20131885 (2020).","journal-title":"Clin. Cancer Res."},{"key":"75554_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno, M. et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol. Hepatol. 4, 611\u2013621 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"75554_CR21","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul, S. A. et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int. J. Cancer 147, 2190\u20132198 (2020).","journal-title":"Int. J. Cancer"},{"key":"75554_CR22","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1001\/jamaoncol.2020.2814","volume":"6","author":"O Klein","year":"2020","unstructured":"Klein, O. et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol. 6, 1405\u20131409 (2020).","journal-title":"JAMA Oncol."},{"key":"75554_CR23","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","volume":"6","author":"RD Kim","year":"2020","unstructured":"Kim, R. D. et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 6, 888\u2013894 (2020).","journal-title":"JAMA Oncol."},{"key":"75554_CR24","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca, A. et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 22, 690\u2013701 (2021).","journal-title":"Lancet Oncol."},{"key":"75554_CR25","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker, J. D. et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J. Clin. Oncol. 36, 1631\u20131641 (2018).","journal-title":"J. Clin. Oncol."},{"key":"75554_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35144-1","volume":"13","author":"D Hsiehchen","year":"2022","unstructured":"Hsiehchen, D. et al. Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nat. Commun. 13, 7477 (2022).","journal-title":"Nat. Commun."},{"key":"75554_CR27","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1200\/OP.24.00167","volume":"20","author":"F Battaglin","year":"2024","unstructured":"Battaglin, F. & Lenz, H. J. Clinical applications of circulating tumor DNA profiling in GI cancers. JCO Oncol. Pr. 20, 1481\u20131490 (2024).","journal-title":"JCO Oncol. Pr."},{"key":"75554_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","volume":"82","author":"S Hwang","year":"2025","unstructured":"Hwang, S. et al. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. J. Hepatol. 82, 649\u2013657 (2025).","journal-title":"J. Hepatol."},{"key":"75554_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.21873\/cgp.20203","volume":"17","author":"A Rizzo","year":"2020","unstructured":"Rizzo, A., Ricci, A. D., Tavolari, S. & Brandi, G. Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives. Cancer Genomics Proteom. 17, 441\u2013452 (2020).","journal-title":"Cancer Genomics Proteom."},{"key":"75554_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41588-020-00752-4","volume":"53","author":"C Valero","year":"2021","unstructured":"Valero, C. et al. The association between tumor mutational burden and prognosis is dependent on treatment context. Nat. Genet. 53, 11\u201315 (2021).","journal-title":"Nat. Genet."},{"key":"75554_CR31","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/1078-0432.CCR-25-2566","volume":"32","author":"C Yeh","year":"2026","unstructured":"Yeh, C. et al. Acquired high tumor mutational burden and activity of immunotherapy after targeted therapy in microsatellite stable colorectal cancer. Clin. Cancer Res. 32, 1100\u20131109 (2026).","journal-title":"Clin. Cancer Res."},{"key":"75554_CR32","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho, M. A. et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity 47, 1083\u20131099 e1086 (2017).","journal-title":"Immunity"},{"key":"75554_CR33","first-page":"121","volume":"1","author":"AB Ward","year":"2020","unstructured":"Ward, A. B. et al. Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. Med. Comm. 1, 121\u2013128 (2020).","journal-title":"Med. Comm"},{"key":"75554_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41392-025-02356-y","volume":"10","author":"G Shi","year":"2025","unstructured":"Shi, G. et al. First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study. Signal Transduct. Target. Ther. 10, 260 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"75554_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60757-7","volume":"16","author":"D Hsiehchen","year":"2025","unstructured":"Hsiehchen, D. et al. Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial. Nat. Commun. 16, 5819 (2025).","journal-title":"Nat. Commun."},{"key":"75554_CR36","doi-asserted-by":"publisher","first-page":"e0140712","DOI":"10.1371\/journal.pone.0140712","volume":"10","author":"RB Lanman","year":"2015","unstructured":"Lanman, R. B. et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS ONE 10, e0140712 (2015).","journal-title":"PLoS ONE"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75554-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75554-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75554-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T23:25:48Z","timestamp":1787527548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75554-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75554"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75554-z","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.H. has served as a consultant for AztraZeneca. H.Z. is a co-founder of Quotient Therapeutics and Jumble Therapeutics, and has consulted for Newlimit and Alnylam Pharmaceuticals. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8886"}}